Overview

Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
Phase:
Phase 4
Details
Lead Sponsor:
Taizhou Mabtech Pharmaceutical Co.,Ltd
Treatments:
Infliximab